Regeneron Says CHMP Recommends Libtayo For EU Approval As Adjuvant Treatment Of CSCC

Regeneron Pharmaceuticals (REGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Libtayo (cemiplimab) as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and radiation. This recommendation, supported by Phase 3 C-POST trial data demonstrating a 68% reduction in disease recurrence or death compared to placebo, precedes an expected final decision from the European Commission in the coming months. The development follows Libtayo's recent U.S. FDA approval for the same indication, signaling significant market expansion potential for the drug.

Analysis

Regeneron Pharmaceuticals (REGN) has achieved a significant regulatory milestone with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopting a positive opinion for Libtayo (cemiplimab). This recommendation targets Libtayo as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and radiation, marking a crucial step towards market expansion in Europe. This follows the drug's recent U.S. FDA approval for the same indication earlier this month, positioning Libtayo for a broader global commercial footprint.

The positive opinion is underpinned by compelling data from the global Phase 3 C-POST trial, which demonstrated Libtayo's ability to reduce the risk of disease recurrence or death by 68% compared to placebo. This robust efficacy data highlights a substantial clinical benefit for patients in this high-risk population. Furthermore, the trial indicated a manageable safety profile, with adverse event rates being comparable between Libtayo (91%) and placebo (89%) groups.

The anticipated final decision from the European Commission in the coming months, coupled with the prior U.S. approval, underscores Libtayo's potential to become a standard of care in adjuvant CSCC. This regulatory progress not only validates Regeneron's oncology pipeline but also suggests a positive outlook for the company's revenue growth and market share in a specialized oncology segment.

Key Decisions for Investors

• Investors should re-evaluate Regeneron's (REGN) revenue projections for Libtayo, considering the expanding market opportunity following positive European regulatory momentum and prior U.S. approval.
• Monitor the European Commission's final decision and subsequent commercial launch performance in both the U.S. and EU to gauge the drug's market penetration and financial impact.
• Assess the long-term competitive landscape in adjuvant CSCC, as Libtayo's strong efficacy data positions it as a potential standard of care.